News – 2022

Collaboration to leverage Caris’ comprehensive (WES/WTS) molecular profiling technologies and large clinico-genomic database to elucidate biomarkers associated with response to HMBD-001, with the goal to increase the probability of clinical successIRVING, Texas and SINGAPORE, December 6, 2022 – Caris Life Sciences®(Caris), the leading molecular science and technology company actively developing and delivering innovative solutions to … Continue reading "Caris Life Sciences and Hummingbird Bioscience Enter Into Collaboration to Advance Clinical Development of Anti-HER3 Therapy"

VISTA blockade with HMBD-002 reprograms tumor associated macrophages and promotes cytotoxic T-cell response in preclinical studiesHMBD-002 in combination with anti-PD-1 treatment shows enhanced anti-tumor efficacy compared to monotherapy arms in preclinical studies HMBD-002 is currently being assessed in a Phase 1 study to determine the recommended Phase 2 dose as a monotherapy and in combination […]

San Francisco & Houston & Singapore, November 1, 2022 – Hummingbird Bioscience, a data-driven precision biotherapeutics company discovering and developing transformative biologic medicines for hard-to-treat diseases, today announced that Chief Financial Officer Josh House and Chief Development Officer Leah DiMascio will participate in one-on-one investor meetings at the Credit Suisse 31st Annual Global Healthcare Conference […]

San Francisco & Houston & Singapore, September 23, 2022 – Hummingbird Bioscience, a data-driven precision biotherapeutics company discovering and developing transformative biologic medicines for hard-to-treat diseases, today announced the official opening of its office and research facilities at the Singapore Science Park. Deputy Prime Minister and Coordinating Minister for Economic Policies Heng Swee Keat officiated […]

San Francisco & Houston & Singapore, September 19, 2022 – Hummingbird Bioscience, a data-driven precision biotherapeutics company discovering and developing transformative biologic medicines for hard-to-treat diseases, today announced that Jerome Boyd-Kirkup, Ph.D., Hummingbird Bioscience’s Chief Scientific Officer, will present at the 2nd Annual VISTA Symposium on September 23, 2022.“VISTA is a promising therapeutic target we […]

– HMBD-001 is a proprietary anti-HER3 antibody in an ongoing Phase 1 trial targeting multiple solid tumors– HMBD-001 has the potential to fully block both ligand-dependent and -independent HER3 signalingSan Francisco & Houston & Singapore, September 8, 2022 – Hummingbird Bioscience, a data-driven precision biotherapeutics company discovering and developing transformative biologic medicines for hard-to-treat diseases, […]

San Francisco & Houston & Singapore, September 6, 2022 – Hummingbird Bioscience, a data-driven precision biotherapeutics company discovering and developing transformative biologic medicines for hard-to-treat diseases, today announced that Chief Executive Officer Piers Ingram, Ph.D., and Chief Financial Officer Josh House will participate in one-on-one investor meetings at Morgan Stanley’s 20th Annual Global Healthcare Conference […]

Hummingbird Bioscience, an innovative clinical-stage biotech company focused on developing precision therapies against hard-to-drug targets in cancer and autoimmune disease, today announced the publication of preclinical data for HMBD-002, a novel anti-VISTA antibody therapeutic, in the Journal for ImmunoTherapy of Cancer, a peer-reviewed journal of the Society for Immunotherapy of Cancer.